Who is sponsoring NCT04718376?

NCT04718376 is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT04718376?

Interventions in NCT04718376: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV).

What condition does NCT04718376 study?

NCT04718376 studies Platinum-resistant Ovarian Cancer.

Is NCT04718376 still recruiting?

NCT04718376 is currently terminated. Last updated 7 March 2024.

Last reviewed 2024-03-07 · How we verify

NCT04718376

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer

Terminated Phase 1 Last updated 7 March 2024

What this trial tests

Phase 1 trial testing Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) in Platinum-resistant Ovarian Cancer in 56 participants. Terminated before completion.

Timeline

12 January 2021

Primary endpoint
22 May 2023

22 May 2023

Quick facts

Lead sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	56
Start date	12 January 2021
Primary completion	22 May 2023
Estimated completion	22 May 2023
Sites	7 locations across China

Drugs / interventions tested

Mitoxantrone Hydrochloride Liposome, intravenous injection (IV) — full drug profile →

Conditions studied

Platinum-resistant Ovarian Cancer — all drugs for Platinum-resistant Ovarian Cancer →

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

18 and older, female only, with Platinum-resistant Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.
Nirmala MJ, Kizhuveetil U, Johnson A, G B, et al · · 2023 · cited 86× · PMID 36926304 · DOI 10.1039/d2ra07863e
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304
Recent advanced lipid-based nanomedicines for overcoming cancer resistance.
Dechbumroong P, Hu R, Keaswejjareansuk W, Namdee K, et al · · 2024 · cited 11× · PMID 39050885 · DOI 10.20517/cdr.2024.19

Verify or expand the search:

Other trials of Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)

Trials testing the same drug.

NCT04902027 — A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers · Phase 1 · completed
NCT04719065 — A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor · Phase 1 · unknown

Other recruiting trials for Platinum-resistant Ovarian Cancer

Currently open trials in the same condition.

NCT07109414 — Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · Phase 2, PHASE3 · active not recruiting
NCT06321484 — Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer · Phase 1 · recruiting
NCT06515613 — A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors · Phase 1 · recruiting
NCT04787289 — A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT05551507 — IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer · Phase 1, PHASE2 · recruiting

Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04718376 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last refreshed: 7 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04718376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing